Skip to main content

Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2.


AUTHORS

Luo N , Formisano L , Gonzalez-Ericsson PI , Sanchez V , Dean PT , Opalenik SR , Sanders ME , Cook RS , Arteaga CL , Johnson DB , Balko JM , . Oncoimmunology. 2018 ; 7(6). e1438106

ABSTRACT

Immunotherapies targeting programmed cell death protein 1 (PD-1) or its ligand, programmed cell death ligand 1 (PD-L1), dramatically improve the survival of melanoma patients. However, only ∼40% of treated patients demonstrate a clinical response to single-agent anti-PD-1 therapy. An intact tumor response to type-II interferon (i.e. IFN-γ) correlates with response to anti-PD-1, and patients with or acquired resistance may harbor loss-of-function alterations in the JAK/STAT pathway, which lies downstream of the interferon gamma receptor (IFNGR1/2). In this study, we dissected the specific roles of individual JAK/STAT pathway members on the IFN-γ response, and identified JAK1 as the primary mediator of JAK/STAT signaling associated with IFN-γ-induced expression of antigen-presenting molecules MHC-I and MHC-II, as well as PD-L1 and the cytostatic response to IFN-γ. In contrast to the crucial role of JAK1, JAK2 was largely dispensable in mediating most IFN-γ effects. In a mouse melanoma model, inhibition of JAK1/2 in combination with anti-PD-L1 therapy partially blocked anti-tumor immunologic responses, while selective JAK2 inhibition appeared to augment therapy. Amplification of JAK/STAT signaling in tumor cells through genetic inhibition of the negative regulator potentiated IFN-γ response and , and may be a target to enhance immunotherapy efficacy.



Tags:

VIEW MORE EVENTS >